Atalanta Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
51 Sleeper St Fl 7, Boston, Massachusett...Phone Number
(339) 330-8780Website
www.atalantatx.comRevenue
$14.6 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Atalanta Therapeutics
Based out of Boston, MA, Atalanta Therapeutics is a biotechnology company with a focus on neurodegenerative disease treatments.Explore more
Atalanta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atalanta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Atalanta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Atalanta Therapeutics
Atalanta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Atalanta Therapeutics has new funding data
Earning: See what the market has to say on Atalanta Therapeutics recently announced quarterly report
Product Launch: Get notified when Atalanta Therapeutics launches new products
Click to see if Atalanta Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Atalanta Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Atalanta Therapeutics
Find 3 more new buyers
Compare Similar Companies to Atalanta Therapeutics
Compare insights from companies similar to Atalanta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atalanta Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atalanta Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atalanta Therapeutics.
Atalanta Therapeutics financials insights
Gather financial insights about Atalanta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$110M
2025
Series B
$97M
Atalanta Therapeutics Tech Stack
A closer look at the technologies used by Atalanta Therapeutics
Most Recent Scoops
Project
Atalanta Therapeutics has shown an interest in procuring solutions related to personalization such as Capillary Engage+.
Spending/Investment
Project
Atalanta Therapeutics is considering the purchase of solutions related to e-commerce platform such as TrueCommerce eCommerce Platform.
Retail/Store Systems, Spending/Investment, eCommerce
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Atalanta Therapeutics News & Media
Atalanta Therapeutics Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy
BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the publication of preclinical data in the journal Epilepsia demonstrating proof-of-mechanism of its investigational di-siRNA therapy, ATL-201, in a mouse model of KCNT1-related epilepsy. Durable seizure suppression and behavioral improvements were observed over 6 months, with favorable tolerability. The company plans to submit anFrom research to development: Atalanta bags $97m to advance two RNAi therapies
Atalanta Therapeutics has closed an oversubscribed $97 million Series B financing round to move two RNAi therapies for neurological diseases into clinical trials.Atalanta Gets $97 Million Series B to Target Neurological Disorders With RNAi - BioSpace
The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and Alzheimer’s.Atalanta Therapeutics Raises $75M in Series B Funding
Atalanta Therapeutics, a Boston, MA-based company developing RNA interference (RNAi) to treat neurological diseases, raised $75M in Series B funding. The round was led by EQT Life Sciences, co-led by Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, abrdn, Inc., Mirae Asset Financial Group and existing investor F-Prime Capital. The Series B […] The post Atalanta Therapeutics Raises $75M in Series B Funding appeared first on FinSMEs.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atalanta Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of Boston, MA, Atalanta Therapeutics is a biotechnology company with a focus on neurodegenerative disease treatments.... Read More
